Third, GPR30 was detected in nearly 60 % of breast cancer cases, and coexpression of GPR30 and ERα was confirmed in about 40 % of breast cancer cases [9], indicating the clinical basis of GPR30-induced TAM resistance. Here, GPER1 is linked to breast carcinoma.